GPCR/G protein

All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B4719 BambuterolSummary: long acting beta-adrenoceptor agonist -
B2264 Dapoxetine HClSummary: Selective serotonin reuptake inhibitor -
B3394 GuanfacineSummary: selective α2A receptor agonist -
B2263 BMY 7378Summary: 5-HT1A partial agonist and α1D adrenoceptor antagonist -
B1986 NedaplatinSummary: DNA synthesis inhibitor -
B2262 AgomelatineSummary: MT1/MT2 / 5-HT2C agonist -
B1787 MethyldopaSummary: alpha-2 adrenergic receptor agonist -
B2261 ZolmitriptanSummary: Potent 5-HT1B/1D/1F agonist -
B1370 Synephrine HCl1 CitationSummary: Sympathomimetic α-adrenergic receptor (AR) agonist -
B1369 Indacaterol MaleateSummary: Ultra-long-acting β-adrenoceptor agonist
